HealthTree Logo HealthTree Foundation
Donate
HealthTree Logo
Donate
Personal Health Record
  • My Feed
  • Recently viewed

Learn

  • Topics
  • Events

Explore

  • Find treatments & trials
  • Participate in research
  • Find a coach
  • Find a specialist
  • Talk to a patient navigator
  • Get involved
  • For researchers
  • For healthcare providers
  • About us
  • Get involved
  • For researchers
  • For healthcare providers
  • About us

Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

  • Treatments and trials you qualify for
  • Education for your stage of care
  • Financial support for your medications
  • Solutions to your side effects
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Learn more about HealthTree
Trial match for you
Matched on subtype and prior lines
Financial help
Support program for your current medication
Coach support
Coach suggestion with your same treatment path
Video

Ask the Expert: Relapsed/Refractory Multiple #Myeloma | Abhishek Pandey, MD

Posted by
HealthTree Logo HealthTree
• May 13, 2026

Description

Abhishek Pandey, MD answers patient and caregiver questions about relapsed and refractory multiple myeloma at the HealthTree Myeloma Roundtable in Miami, FL (Apr 2026).

Related Content

  • Video Etentamig in Heavily Pretreated Myeloma: Phase 3 CERVINO Results | IMS 2026 #myeloma
  • Video First Relapse in Myeloma: Barriers to CAR-T, Bispecifics & New Treatments | IMS 2026
  • Video Should You Use the Best Myeloma Treatments Early or Save Them for Relapse?
  • Video Etentamig for Relapsed Multiple Myeloma: New Bispecific Shows Strong Results, Low CRS | IMS 2026
  • Video Should Everyone Get CAR-T at First Relapse in Multiple Myeloma? EMPOWER Consortium Data | IMS 2026
  • Video Real-World Treatment Sequencing After CAR-T vs Bispecific Antibodies in Multiple Myeloma | EHA 2026